<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856413</url>
  </required_header>
  <id_info>
    <org_study_id>BT 987</org_study_id>
    <secondary_id>2012-002516-51</secondary_id>
    <nct_id>NCT01856413</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant</brief_title>
  <acronym>ZEUS</acronym>
  <official_title>An Open, Prospective, Single Arm Study Investigating Efficacy and Safety of Human Hepatitis B Immunoglobulin Zutectra in Liver Transplanted Patients - the ZEUS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotest</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AMS Advanced Medical Services GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who receive liver transplantation for hepatitis B virus (HBV) induced liver failure
      require longterm therapy to prevent HBV reinfection of the transplanted liver. The approved
      preventative treatment is a combination of antihepatitis B immunoglobulin (HBIg) and oral
      antiviral medication. In the first 6 months after liver transplantation, patients receive
      treatment with intravenous HBIg to maintain blood antihepatitis B (antiHBs)antibody
      concentrations above 100 IU/L, the level considered safe for preventing hepatitis B
      reinfection.

      Zutectra is an HBIg preparation for subcutaneous injection that is approved in the EU for the
      'prevention of HBV reinfection in HBV DNA negative patients ≥ 6 months after liver
      transplantation for hepatitis B induced liver failure'. The purpose of this study is to show
      that earlier subcutaneous HBIg treatment with Zutectra after liver transplantation can
      prevent hepatitis B reinfection.

      Treatment with subcutaneous HBIg (Zutectra) at home is manageable for the majority of
      patients and is more convenient for patients compared to intravenous treatment that must take
      place in the hospital setting.

      Fourty patients will take part in the study at approximately 19 centres in UK, France, Italy
      and Spain. Patients who are eligible for the study will receive treatment with Zutectra for
      24 weeks.

      During the study, the safety and effectiveness of Zutectra will be assessed by checking for
      symptoms of hepatitis B related infection, as well as monitoring blood levels of antiHBs
      antibodies and hepatitis B surface antigen (HBsAg).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough levels of serum anti-HBs antibody concentrations</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B related re-infections</measure>
    <time_frame>24 weeks</time_frame>
    <description>The number of all patients with hepatitis B related infections will be assessed by monitoring of clinical signs, liver function and measurement of HBsAg and HBV-DNA.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
    <description>The number of adverse events will be documented including safety laboratory parameters reported as AEs.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Zutectra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zutectra</intervention_name>
    <description>Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.</description>
    <arm_group_label>Zutectra</arm_group_label>
    <other_name>Human hepatitis B Immunoglobulin</other_name>
    <other_name>HBIg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained prior to orthotopic liver transplantation (OLT) -
             not more than 3 months before OLT

          -  Historical evidence within the last 4 weeks that HBV-DNA is undetectable at time point
             of signature of Informed Consent

          -  Male and female patients (age 18-75 years)

          -  Patients with the diagnosis of liver failure with hepatitis B infection

          -  Patients undergoing liver transplantation or re-transplantation

          -  HBsAg negative on day 7 or on day 14 after OLT

          -  HBV-DNA undetectable at OLT

          -  Serum HBs antibody concentration on day 7 or on day 14 after OLT ≥ 400 IU/l

          -  Stable patient in a condition which in the opinion of the investigator would permit
             safe participation in the study

          -  Willingness to fill out patient diary

        Exclusion Criteria:

          -  Re-transplantation due to viral recurrence

          -  Positive HIV or HCV test at time of transplantation

          -  HBV-DNA positive at OLT

          -  Patients having received organs from HBsAg positive donors

          -  Pregnancy or unreliable contraceptive measures or lactation period (females only)

          -  Known intolerance to immunoglobulins or comparable substances (e.g. vaccination
             reaction)

          -  Known intolerance to proteins of human origin

          -  Participation in another interventional clinical trial within 90 days before entering
             the study or during the study and/or previous participation in this study (except
             screening failures)

          -  Suspicion of drug and/or alcohol abuse

          -  Inability or lacking motivation to participate in the study

          -  Employee or direct relative of an employee of the CRO, the study site, or Biotest
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Samuel, Professeur</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Paul Brousse, Centre Hepato-Biliaire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Orsola Hospital</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera &quot;G. Brutzu&quot; di Cagliari</name>
      <address>
        <city>Cagliari</city>
        <zip>CA 09135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedale Niguarda Ca Granda-Chirurgia</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedialera Universitaria di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>54124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Tor-Vergata U.O.C.</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Molinette Hospital</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>Hepatitis B virus re-infection</keyword>
  <keyword>HBV-DNA negative</keyword>
  <keyword>Liver transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

